Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

• P. Sonneveld, Ingo G. H. Schmidt-Wolf, +25 authors Hartmut M Goldschmidt
• Journal of clinical oncology : official journal…
• 2012

PURPOSE We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). PATIENTS AND METHODS In all, 827 eligible patients with newly… (More)

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the…

• Christof Scheid, Pieter Sonneveld, +26 authors Henk M. Lokhorst
• Haematologica
• 2014

Renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. This analysis evaluates the prognostic role of renal impairment in patients with myeloma… (More)

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.

• Henk M. Lokhorst, Ingo G. H. Schmidt-Wolf, +25 authors Hartmut M Goldschmidt
• Haematologica
• 2008

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction… (More)

• ‹
• 1
• ›